Quick answer
What is Selank?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk How this site works
Selank is a peptide, grouped on this site under Neuroactive peptides, and the 12 research records kept here are 10 from studies in rats or mice and 2 that do not state what kind of study it is.
The literature search returned 69 records. This site keeps 12 of them, which is 17 per cent of what came back.
What it is
This site puts it in the Neuroactive peptides group.
A tuftsin-family heptapeptide; the retrieved records report inhibition of enkephalin-degrading enzymes and effects on the expression of genes in GABAergic signalling.[1, 2]
Stated in the titles of the cited 2001 Bulletin of Experimental Biology and Medicine and 2017 Frontiers in Pharmacology papers.
What kind of records
The records kept here are animal and laboratory studies only.
That sentence is produced by counting, not by reading. What was counted: no interventional human trial record; 10 rodent and 0 in vitro records among 12.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 57 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of experimental biology and medicine (2001). pmid:11550013
- GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in pharmacology (2017). pmid:28293190